Videos

At 1 year, patients randomized to Rezūm showed a 4.6-point greater improvement on the IPSS symptom score compared with those escalated to combination therapy.

On actionable guidance for community practitioners, Kamat's most emphatic recommendation is early pathology review.

Antoni Vilaseca Cabo, MD, characterizes these results as proof of concept for the local delivery approach, with phase 2 and 3 trials now underway.

Guerrero-Ramos argues that landmark survival data from recent trials justify perioperative immunotherapy in muscle-invasive bladder cancer, while acknowledging that validated tools for individual patient selection remain elusive and that urologists must engage closely with medical oncology to deliver optimal care.

On diagnostic pitfalls, Necchi highlights penile cancer as a particularly common source of delay.

On counseling patients who want to avoid cystectomy, Bogdana Schmidt, MD, MPH, points to trimodality therapy as the established bladder-preserving option, supported by longer-term data and propensity-matched analyses showing outcomes comparable to cystectomy in selected patients.

How teams use PSMA PET to stage prostate cancer: who orders, who reads, and how tumor boards refine treatment when findings conflict.

Daniel J. George, MD, discusses results from a survey examining the experiences and unmet needs of caregivers supporting patients with metastatic prostate cancer.

Learn how PSMA PET reshapes prostate cancer staging, outperforms CT and bone scans, and finds recurrence even at very low PSA.

Sam S. Chang, MD, MBA, highlights 2 studies presented at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco, California, that he believes are particularly impactful for clinicians treating bladder cancer.

The discussion explores how the rising burden of comorbidities and polypharmacy in patients with metastatic castration-sensitive prostate cancer requires clinicians to carefully balance therapy intensification with overall health status, medication interactions, and long-term safety when developing individualized treatment plans.

The discussion introduces how the treatment landscape for metastatic castration-sensitive prostate cancer has evolved, highlighting that patients are now living longer with metastatic disease and often have multiple comorbidities, making long-term tolerability and quality of life key considerations in treatment planning.

Dinesh Singh, MD, emphasizes that radiation reduction begins at the diagnostic stage, favoring low-dose CT scans over standard-dose imaging.

Mustafa J. Saleh, MD, highlights new research exploring whether germline-based polygenic risk scores could help predict outcomes for patients with kidney cancer.

In this video, Gordon A. Brown, DO, FACOS, discusses PTEN deficiency as a prognostic marker and its implications for treatment selection, monitoring, and risk stratification in mHSPC.

Discover essential strategies for managing advanced prostate cancer, including team collaboration, systematic documentation, and patient care best practices.

On Hugo's modular arm architecture, Porter contrasts it with the traditional "boom" design that has dominated robotic surgery for over 2 decades.

Maha H. A. Hussain, MD, FASCO, FACP, outlines the design and key findings from a phase 2 trial of abiraterone plus olaparib vs each agent alone in mCRPC.

Telemedicine has also expanded access, allowing patients to choose either virtual or in-person visits. However, Kaylani Narra, MD, emphasized that limited genetic counseling capacity remains a major barrier.

According to Sophia Kamran, MD, innovation in bladder cancer is expanding treatment options and patient-centered care.

Vignesh T. Packiam, MD, reviews several bladder cancer studies from ASCO GU 2026 that he described as clinically meaningful for practicing urologists.

Rubenstein emphasizes the importance of strong clinical documentation and preparation by billing teams.

Laura Bukavina, MD, MPH, MSc, sat down to discuss the emerging role of ctDNA in guiding treatment decisions for patients with muscle-invasive bladder cancer, drawing on findings from the RETAIN and RETAIN 2 trials.

For asymptomatic renal stones, Mathew D. Sorensen, MD, MS, FACS, said he believes Break Wave could meaningfully influence the long-standing debate between surveillance and early intervention.

Chad Tang, MD, discusses the development of a prognostic model—K-COMPASS—for patients with oligometastatic clear cell renal cell carcinoma.

Healthcare professionals discuss the growing preference for oral hormone therapy over injectables, emphasizing patient control and comfort in treatment choices.

Experts discuss the cardiovascular risks associated with androgen deprivation therapy, comparing Relugolix and Leuprolide's impact on coronary plaque formation.

Gordon A. Brown, DO, FACOS, gives an overview of PTEN biology, distinctions between PTEN loss and deficiency, and the clinical importance of PI3K/AKT pathway activation in prostate cancer progression.

Robert S. Svatek, MD, discusses the background and key findings from the SWOG S1602 trial, evaluating BCG strain differences and intradermal BCG before intravesical therapy for patients with BCG-naïve NMIBC.

Sophia C. Kamran, MD, highlights some of the key bladder cancer trials presented at ASCO GU 2026 from the perspective of a radiation oncologist.